Photocure announces new Cevira patent in Europe
On October 5, 2020, Photocure ASA announced that the European Patent Office granted patent EP 2983780 for the Cevira® device, valid in Europe until April 9, 2034. Cevira is a photodynamic drug-device combination product for treating high-grade cervical dysplasia, a condition linked to HPV. In July 2019, the company licensed global development rights to Asieris Meditech. Asieris has since begun a global Phase III trial for Cevira following a China NMPA approval in July 2020.
- Patent EP 2983780 granted for Cevira until April 2034, securing exclusive rights in Europe.
- Cevira addresses a high medical need for non-surgical treatment of cervical dysplasia.
- None.
OSLO, Norway, Oct. 5, 2020 /PRNewswire/ -- Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira® device in Europe until 2034.
Cevira is a photodynamic drug-device combination product under development for non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure announced that it had entered into a License Agreement providing Asieris Meditech Co., Ltd (Asieris) with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. In July 2020, Asieris received China NMPA's approval to start a global Phase III clinical trial for APL-1702 (Cevira).
The EP 2983780 patent covering the commercial Cevira device in Europe, will expire 09 April 2034.
Notes to editors
About Cevira
Cevira® is a photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade cervical dysplasia. Cevira® is easily placed on the cervix by the gynecologist and removed by the patient, with no disruption of normal daily activities. Only one or two treatments are needed.
About Cervical dysplasia
High-grade cervical squamous intraepithelial lesions (HSIL) is a precancerous condition caused by a persistent HPV infection, a highly prevalent sexually transmitted disease resulting in approximately 10 million cases with high grade disease and > 500 000 new cases of cervical cancer each year. In China, 1
About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com
All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA
CONTACT:
For further information, please contact:
Photocure
Dan Schneider
President and CEO
Tel: +1-609 759-6515
Email: ds@photocure.com
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/photocure/r/photocure-announces-new-cevira-patent-in-europe,c3210191
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/photocure-announces-new-cevira-patent-in-europe-301145438.html
SOURCE Photocure
FAQ
What is the significance of the patent granted to Photocure for Cevira?
When did Photocure announce the patent for Cevira?
What is Cevira and what is its purpose?
Who holds the development rights for Cevira?
What clinical trial is associated with Cevira?
